Pharmaceutical News and Articles

Short-Term Surgical Outcomes at Rural Facilities Similar to Those in More Distant, Urban Facilities

Older patients with stage I to III colon or lung cancer achieve comparable short-term surgical outcomes when they undergo surgery at local rural facilities vers

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA PF’3944 Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Pfizer Inc. (NYSE PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, u

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Cumberland Pharmaceuticals Inc. (Nasdaq CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX RO, ROG OTCQX RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investig

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

CAMBRIDGE, MA ACCESS Newswire February 10, 2026 Moderna, Inc. (NASDAQ MRNA) today announced the U.S. Food and Drug Administration s (FDA) Center for Biologics E

NIH Halts Arm of Clinical Trial Evaluating a Potential Stroke Treatment

The National Institutes of Health (NIH) has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intra

FDA Approves Label Update for Kite’s Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

Keytruda and Keytruda Qlex, Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma

PTC Therapeutics Provides Regulatory Update on Translarna